{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015736","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.887835+00:00","generated_at":"2026-06-24T02:11:03.048487+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Beam Q2 net loss $72M; BEAM-201 IND on clinical hold; cash $1.2B","bullets":["Net loss $72.0M ($1.02/share) vs $76.3M ($1.23) prior year; R&D spend $74.6M (+64% YoY).","BEAM-201 IND placed on clinical hold by FDA July 29; awaiting official letter.","Patient enrollment in BEACON Phase 1/2 for BEAM-101 on track for 2H 2022.","John Lo, Ph.D., appointed Chief Commercial Officer; Amended Verve deal adds CV target.","Cash, cash equivalents and marketable securities $1.2B as of June 30, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015736","json":"https://secwatch.observer/filing/0000950170-22-015736.json","markdown":"https://secwatch.observer/filing/0000950170-22-015736.md","text":"https://secwatch.observer/filing/0000950170-22-015736.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022015736/0000950170-22-015736-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017022015736/beam-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:11:03.048487+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}